Is AI just another hype? Or the key to unlocking drug development potential?

—

With AI’s rapid advancements outpacing Moore’s Law, why hasn’t it dramatically improved the efficiency of pharmaceutical innovation? Dr. Fakhouri explores how AI could help us decipher the "language of biology" and streamline drug discovery, while addressing the myths and challenges that regulatory bodies like the FDA must navigate. What does the future hold for AI in the pharmaceutical landscape that will save thousands of lives with rare disease?

—

About Dr. Tala Fakhouri

Dr. Tala H. Fakhouri, PhD, MPH, is the Associate Director for Data Science and Artificial Intelligence at the FDA's Center for Drug Evaluation and Research (CDER). She leads efforts to develop and implement medical policy around AI in drug development, overseeing an AI policy group and collaborating with external stakeholders. Dr. Fakhouri also works on initiatives related to real-world evidence and digital health technologies, helping shape the future of AI in clinical research and drug development.

—

Disclaimer

The views expressed are the presenter’s and do not constitute agency policy. Any mentions of organizations, companies, stakeholders and the like do not constitute any special recognition or endorsement of the organizations or companies mentioned.

—

Credits:

• Event Production: Smith & Jones Innovation

• Direction & Speaker Support: Jeff Smith

• Production & Stage Management: Michelle Jones

• Stage Design & Lighting: Steve Harper | Indigo Design

• Video Capture: Armosa Studios

• Video Editing: Kyle Blackburn

• Screen Assets & Video Engineer: Hunter Loveridge | Picture This

• Sound Engineer: Uptown! Knauer Center for Performing Arts